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Abstract
Background: Trade and investment liberalization (trade liberalization) can promote or harm health. Undoubtedly it
has contributed, although unevenly, to Asia’s social and economic development over recent decades with resultant
gains in life expectancy and living standards. In the absence of public health protections, however, it is also a
significant upstream driver of non-communicable diseases (NCDs) including cardiovascular disease, cancer and
diabetes through facilitating increased consumption of the ‘risk commodities’ tobacco, alcohol and ultra-processed
foods, and by constraining access to NCD medicines. In this paper we describe the NCD burden in Asian countries,
trends in risk commodity consumption and the processes by which trade liberalization has occurred in the region
and contributed to these trends. We further establish pressing questions for future research on strengthening
regulatory capacity to address trade liberalization impacts on risk commodity consumption and health.
Methods: A semi-structured search of scholarly databases, institutional websites and internet sources for academic
and grey literature. Data for descriptive statistics were sourced from Euromonitor International, the World Bank, the
World Health Organization, and the World Trade Organization.
Results: Consumption of tobacco, alcohol and ultra-processed foods was prevalent in the region and increasing in
many countries. We find that trade liberalization can facilitate increased trade in goods, services and investments in
ways that can promote risk commodity consumption, as well as constrain the available resources and capacities
of governments to enact policies and programmes to mitigate such consumption. Intellectual property provisions
of trade agreements may also constrain access to NCD medicines. Successive layers of the evolving global and
regional trade regimes including structural adjustment, multilateral trade agreements, and preferential trade
agreements have enabled transnational corporations that manufacture, market and distribute risk commodities to
increasingly penetrate and promote consumption in Asian markets.
Conclusions: Trade liberalization is a significant driver of the NCD epidemic in Asia. Increased participation in
trade agreements requires countries to strengthen regulatory capacity to ensure adequate protections for public
health. How best to achieve this through multilateral, regional and unilateral actions is a pressing question for
ongoing research.
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Background
The rate of economic change in Asia over recent decades
has been unprecedented. According to International
Monetary Fund (IMF) data, for example, China’s share
of Global GDP (PPP) rose from 2.2% in 1980 to 15.6%
in 2013 [1]. India and China alone have doubled eco-
nomic output per capita in less than 20 years, twice the
rate achieved during the industrial revolution in the
West [2]. In some countries social development has also
been considerable; life expectancy in Vietnam, for ex-
ample, increased from 65 to 75 and its Human Develop-
ment Index (HDI) score rose from 0.44 to 0.62 between
1990 and 2011 [3]. An important driver of Asia’s eco-
nomic and social progress has been the systematic reduc-
tion in barriers to cross-border trade and investment,
from hereafter called ‘trade liberalization’. In recent de-
cades, and especially since the Asian Financial Crisis, trade
liberalization in Asia has accelerated in both pace and
scope, initially through unilateral structural adjustment
and the multi-lateral (General Agreement on Tariffs and
Trade/World Trade Organization) system, and more re-
cently through the proliferation of a ‘noodle bowl’ of
preferential trade agreements (PTAs) at the bilateral
and regional levels [4]. Indicative of this, bilateral or re-
gional PTAs involving at least one Asian country in-
creased from 46 in 1998 to 257 in 2013, of which 132
had been ratified [5]. Such processes have facilitated the
development of the regions advanced cross-border pro-
duction networks which underlie its status as a global
‘industrial dynamo’ [6,7].
Trade liberalization can work for or against health.
On the one hand, it can promote the transfer of goods,
services, investments and technologies that promote
health directly through for example expanding access to
nutritious foods and essential medicines, or indirectly
by stimulating economic growth and employment. On
the other, the benefits for health remain contested with
demonstrated disparities in trade and investment re-
lated economic growth between countries, exacerbated
income inequalities within countries, and heightened
economic and food insecurity [8-12]. In the absence of
public health protections, trade liberalization is also an
important ‘upstream’ determinant of non-communicable
diseases (NCDs) which for the purposes of this paper
include cardiovascular disease (CVD), cancer, type-2 dia-
betes and chronic respiratory diseases (CRD) [13-16].
NCDs are, alongside declining yet still prevalent rates of
infectious diseases, the leading causes of death and disabil-
ity in Asia, and excluding Sub-Saharan Africa, in the world
today [17,18].
In this paper we conceptualize trade liberalization as a
driver of NCDs through two main pathways. First, it can
facilitate the global diffusion of ‘risk commodities’ –
tobacco, alcohol and ultra-processed foods – across
borders. A key mechanism is transnational risk commodity
corporations (TRCCs), those that manufacture, market and
distribute such commodities on a global scale. Trade
liberalization allows TRCCs to rapidly move investments,
technologies, production capacity, raw materials and final
products across borders and thereby drive risk commodity
consumption transnationally [19-21]. Growth in risk com-
modity markets has stagnated in high-income countries,
but is rapidly expanding in lower-middle income (L-MICs)
and upper-middle income countries (U-MICs) as TRCCs
seek new profit opportunities from the burgeoning middles
class consumers of Asia [21,22]. Although trade remains
important, foreign direct investment (FDI) is the most sig-
nificant strategy used by TRCCs to penetrate new markets
and grow transnationally [13,20,23,24]. Subsequently, FDI-
inflows are positively correlated with risk commodity con-
sumption rates and the prevalence of NCDs in L-MICs
and U-MICs [21,25]. Since 1980 Asia has been the recipi-
ent of more FDI than any other developing region; nearly a
quarter of the world’s total in 2011 [26,27].
Second, trade liberalization can strengthen the intel-
lectual property rights of transnational pharmaceutical
corporations and TRCCs. As it relates to pharmaceuti-
cals, this can potentially constrain access to medicines
and technologies used in the prevention or treatment of
NCDs. While patent-ownership is concentrated in firms
located in the US, EU and Japan (the top-10 largest
pharmaceutical companies are located in the US and EU
and have 46% of global market share) the greatest need
for NCD-related medicines is located in low- and middle-
income countries [28]. Trade related intellectual property
rights also pertain to the protection of trademarks, brand
names, product logos and trade secrets, with direct im-
plications for policy mechanisms targeting NCD risk
commodities including advertising restrictions, mandatory
product labelling and product content disclosures [29].
Yet while the magnitude and implications of the NCD
burden in Asia have been elucidated [17,30,31], little is
known about the role of trade liberalization as a ‘cause
of the causes’ of NCDs in the region [32]. Using market
data and a synthesis of existing literature, this paper de-
scribes how these interconnected processes – that of trade
liberalization, the activities of TRCCs and risk commodity
consumption, and access to NCD medicines – are unfold-
ing in Asia. It is structured as follows. First we demonstrate
the trends and scale of risk commodity consumption
across select countries in the region and elaborate on the
social and economic costs of such consumption. Second
we describe the processes by which trade and investment
liberalization has occurred in the region to date and how it
is most likely to occur in the future. In this section we
describe the successive ‘layers’ of the global trade regime
that have had a bearing on risk commodity consumption,
including liberalization through structural adjustment
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programmes and unilateral liberalization, the multilateral
system, and the growing importance of bilateral and re-
gional PTAs including the Trans Pacific Partnership (TPP)
agreement. We finish by outlining some pressing questions
for a future research agenda on strengthening regulatory
capacity to address risk commodity consumption and
NCDs in the region.
Methods
The countries included in this analysis, henceforth
termed ‘Asia’, were the Association of Southeast Asian
Nations plus three (ASEAN + 3) grouping of countries:
Brunei Darussalam, Cambodia, Indonesia, Laos, Malaysia,
Myanmar, the Philippines, Singapore, Thailand, and
Vietnam (ASEAN), and China, Japan and South Korea
(+3). These countries were chosen because of their partici-
pation in extensive trade and investment liberalization ac-
tivities at the bilateral, regional and multilateral levels over
the previous two decades. We also included India because
of its large population size, economic and political import-
ance, and because it is a significant source of patented
generic NCD medicines for countries in the region.
Countries were categorized by World Bank income
status as high-income (H-IC), upper-middle income (U-
MIC), lower-middle income (L-MIC) and low-income
(L-IC). We conducted a semi-structured literature search
of scholarly databases (MEDLINE, Scopus) and internet
sources (Google Scholar, Google, Google Books) using a
combination of three categories of search terms (Table 1)
to identify relevant journal articles.
We also searched institutional websites to identify
relevant grey literature and sourced detailed market re-
ports for tobacco, alcohol and processed foods from
Euromonitor International for all countries except Brunei
Darussalam, Laos, Cambodia and Myanmar. Data for de-
scriptive statistics were sourced from the World Bank
World Development Indicators, United Nations Develop-
ment Programme (UNDP) Human Development Index,
World Health Organization (WHO) Global Health Data
Repository, and WHO NCD Country Profiles. Tobacco,
alcohol and processed food consumption data were sourced
from Euromonitor Passport Global Market Information
Database, 2013 edition, covering 1998-2012 with projec-
tions to 2017. Data were extracted for H-IC, U-MIC and
L-MIC countries. Data for Brunei Darussalam, Laos,
Cambodia and Myanmar were not available [33].
The regional context
Economic growth in Asia is closely tied to the Asian epi-
demiological transition [31]. Economic development in
Asia is likely to continue apace. By 2025, four of the
world’s largest ten economies will be in the region and
account for nearly half of global economic output. Seven
countries are likely to lead this: China, India, Indonesia,
Japan, South Korea, Thailand and Malaysia. Yet an emer-
ging epidemic of NCDs in the region could potentially
slow this ‘march to prosperity’ [6]. Some nations are also
marching faster than others, with vast economic and
social disparities between countries. Table 2 provides a
comparison of economic, social and demographic indi-
cators across these countries.
According to World Bank data there is a 57-fold dif-
ference in GNI per capita (Atlas method) between
Singapore and Cambodia. In India and Laos, more than
two thirds of the population live on less than $2 per day,
the World Bank’s measure of absolute poverty [3]. Rapid
demographic transition is underway in many countries,
with some of the highest rates of rural-urban migration
and population ageing globally [31,34]. By 2030, 2.7 bil-
lion Asians or 55% of 4.9 billion, will be urbanized [34].
The region is also politically and culturally diverse. Polit-
ical systems range from Marxist-Leninist Communism
in Laos and Vietnam, to unitary authoritarian parliamen-
tary systems in Singapore and Indonesia, to the world’s
largest parliamentary democracy in India [35]. It is
within this broad context of diversity that the NCD epi-
demic plays out in Asia.
The rise of NCDs and risk commodity consumption
patterns in Asia
In 2008, across the countries we include in this analysis,
17 million people died from NCDs accounting for 65%
of total deaths [36]. Of these, 93% occurred in U-MICs
and L-MICs primarily in China and India. This figure
Table 1 Search categories and terms used
Categories Search terms
Disease and risk factor specific Noncommunicable disease, chronic disease, cardiovascular disease, diabetes, chronic obstructive pulmonary
disease, cancer, stroke, obesity, hypertension, blood glucose, blood cholesterol, tobacco, smoking, alcohol,
processed food, packaged food, snack food, medicine, drugs.
Economic and social burden specific Economic, financial, income, loss, cost, expenditure, GDP, economic burden, social burden, poverty,
microeconomic, macroeconomic, productivity, out-of-pocket health care, socio-economic, inequity, inequality.
Trade liberalization specific Trade liberalization, market integration, foreign direct investment, investment liberalization, trade agreements,
World Trade Organization, globalization, policy space, trade agreement, trans-pacific partnership, corporations,
transnational corporations, transnational tobacco, transnational alcohol, transnational food and beverage,
state-owned enterprises.
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accounted for nearly half of the 36 million NCD-related
deaths globally the same year [18]. Regional mortality
patterns are given in Table 3. Although the proportion
of total deaths attributable to NCDs declined with gross
national income (GNI) per capita, the proportion of NCD
deaths among populations under 60 years of age, or those
in the most economically productive age bracket, in-
creased [37]. In Cambodia, for example, 47% of all NCDs
deaths were in this demographic whereas in Japan this fig-
ure was just 9%. Age-standardised deaths rates were also
considerably higher in L-ICs and L-MICs. For example,
the NCD-related death rates for males and females in the
poorest country Myanmar was approximately twice that
of Singapore the wealthiest.
Differences between countries reflect variations in
population-level determinants of NCDs. These include
ageing populations, levels of educational attainment, the
characteristics of urban environments, cultural and soci-
etal norms, and the extent to which the political and
policy environments are protective [16,38,39]. Among
the most significant determinants driving demand for
risk commodities are rising income levels and rates of
urbanization [18,30,37,40]. Yet these ‘demand-side’ factors
can only partly explain global variation in consumption.
They are less significant in countries with high levels of
market penetration by TRCCs [14,29,41,42], implicating
these commercial actors as important drivers of risk com-
modity consumption and NCDs in the region.
Tobacco use is the most significant preventable risk
factor for CVD, chronic respiratory diseases and cancers
of the lung, larynx, pancreas, stomach, bladder and cervix.
Smoking prevalence differs significantly from 53% among
males in Indonesia to 24% in Singapore. In the H-ICs
cigarette consumption is declining, but expanding rapidly
in China, Indonesia and Vietnam (Figure 1). In China,
consumption exceeds that of the H-ICs. It is the region’s
tobacco epicentre with over 274 million daily smokers in
2012 [43]. Of these smokers 1.2 million die every year, a
figure expected to rise to 3.5 million by 2030. It is also the
world’s largest tobacco producer with an output of 2.5 tril-
lion cigarettes in 2012, accounting for approximately 43%
of global tobacco production [43-45]. Cigarette consump-
tion data for India (Figure 1) should be interpreted with
caution because most tobacco is consumed as bidi ciga-
rettes which are largely manufactured in the informal sec-
tor (i.e. not captured by our market data) [46]. However,
although the use of chewing tobacco is prevalent in India
it demonstrates a relatively lower prevalence of tobacco
use (Table 3) possibly due to its strong track record of to-
bacco control regulation [47,48].
All countries in the region have adopted tobacco con-
trol policies, and all except Indonesia are signatory to
the Framework Convention on Tobacco Control (FCTC).
In many countries including China, Thailand and Vietnam
the state plays a significant role in the production, promo-
tion and distribution of tobacco products [49]. In China
for example, the market is monopolised by the state-
owned enterprise China National Tobacco Corporation
[50], which had a 96.9% market share in 2012 [43]. Justi-
fications for this policy contradiction usually centre on
poverty alleviation, although this view has been discre-
dited [31,49].
Table 2 Country profiles including economic, social and population indicators
Country (ranked
by descending
GNI)
Economic and social indicators (2013) (1, 2) Population (2013) (1)
World Bank
Income Group
$GNI per capita
(Atlas method, $US)
% living
on < $2 day
Human Develop.
Index 2013 (1990)
Urban
(%)
Size
(mill)
Life exp. birth
2011 (1990)
% 65 years
or above
(% aged 0-14)
Singapore High income 54,040 … 0.9 (0.76) 100 5.4 82 (76) 10 (16)
Japan 46,140 … 0.89 (0.84) 92 127.3 83 (79) 25 (13)
Brunei Darussalam 31,5902009 … 0.85 (0.79) 77 0.4 78 (74) 4 (25)
South Korea 25,920 … 0.89 (0.75) 84 50.2 81 (71) 12 (15)
Malaysia Upper middle
income
10,400 2.32009 0.77 (0.64) 74 29.7 75 (70) 5 (26)
China 6,560 27.22009 0.72 (0.5) 53 1357.4 75 (69) 9 (18)
Thailand 5,370 4.12010 0.72 (0.57) 35 67.0 74 (72) 10 (18)
Indonesia Lower middle
income
3,580 46.12010 0.68 (0.48) 52 249.9 71 (62) 5 (29)
Philippines 3,270 41.52009 0.66 (0.58) 49 98.4 69 (65) 4 (34)
Vietnam 1,730 43.42008 0.64 (0.44) 32 89.7 76 (65) 7 (23)
India 1,570 68.72010 0.59 (0.41) 32 1252.1 66 (58) 5 (29)
Laos 1,460 662008 0.57 (0.38) 36 6.8 68 (54) 4 (35)
Cambodia Low income 950 49.52009 0.58 20 15.1 71 (55) 4 (31)
Myanmar … … 0.52 (0.31) 34 53.3 65 (57) 5 (25)
Data sources: 1 =World Bank World Development Indicators; 2 = United Nations Development Programme Human Development Index.
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Table 3 Country NCD mortality and metabolic risk factor profiles
Countries (ranked
by descending GNI
per capita)
Total deaths from NCDs
(000’s) (2008) (1)
NCD death
rates per
100,000*
(2008) (1)
Mortality by cause (% of total deaths, all ages)
(1, 2) (2014)
Metabolic/behavioural risk factors, prevalence (%)
(2008) (1)
CMPM NCDs NCDs in those
<60 years old
(2008)
CVD Cancer CRD Diabetes Tobacco
use*†
Over-
weight*‡
Obesity*‡ Raised blood
pressure*§
Raised blood
glucose*¶
M F Both sexes M F M F M F M F M F M F
Singapore 10.1 7.8 17.9 372 239 19 76 22 31 30 3 1 24 4 34 26 7 7 40 34 8 6
Japan 473.2 435.5 908.8 337 178 13 79 9 29 30 7 1 34 11 30 19 6 4 47 41 9 7
Brunei Darussalam 0.5 0.5 1.0 534 489 9 80 36 34 17 7 11 32 4 36 25 9 7 33 23 9 6
South Korea 112.3 96.7 209.0 465 247 8 79 19 25 30 5 4 50 5 34 29 7 8 33 28 7 6
Malaysia 50.4 39.1 89.5 606 436 16 73 31 36 15 7 3 41 2 42 46 10 17 37 32 11 10
China 4324.0 3675.4 7998.8 665 495 5 87 20 45 23 11 2 49 2 26 25 5 7 40 36 10 9
Thailand 227.1 191.3 418.4 792 541 18 71 29 29 17 9 4 36 2 27 37 5 12 36 32 7 7
Indonesia 582.3 481.7 1064.0 757 538 22 71 31 37 13 5 6 53 3 16 26 3 7 39 36 6 7
Philippines 175.7 133.9 309.5 712 483 25 67 41 33 10 5 6 35 8 25 28 5 8 35 30 6 6
India 2967.6 2273.8 5241.4 782 571 28 60 35 26 7 13 2 25 2 10 12 1 2 33 32 10 10
Vietnam 208.1 222.0 430.1 687 508 16 73 23 33 18 7 3 40 1 10 11 1 2 36 30 7 7
Laos 12.1 11.7 23.8 849 689 43 48 36 22 11 5 2 41 3 10 16 1 4 34 30 … …
Cambodia 31.1 25.5 56.6 958 592 37 52 47 24 13 4 2 42 3 11 13 2 3 31 25 4 5
Myanmar 125.8 116.6 242.5 737 570 30 59 29 25 11 9 3 32 10 13 23 2 6 41 37 5 7
Total 17011.03
CMPM = Communicable, maternal, peri-natal and malnutrition related; CRD = Chronic respiratory diseases; CVD = Cardiovascular diseases; * = age-standardised; † = 15 years and older, currently smoking any tobacco
product; ‡ = 20 years and older; § = systolic blood pressure ≥ 140 OR diastolic blood pressure ≥ 90 OR on medication for raised blood pressure; ¶ = 25 years and older, raised fasting blood glucose (≥7.0 mmol/L or on
medication); Data sources: 1 =WHO Global Health Data Repository; 2 =WHO NCD country profiles (2014).
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These observations discount the combined role of
trade liberalization and transnational tobacco corpora-
tions (TTCs) as consumption drivers in these countries.
However, evidence suggests that TTCs may still pro-
mote consumption in state-dominated markets through
stimulating more intensive competition (including price
competition), facilitating illicit trade in foreign tobacco
products and in some cases by aggressively lobbying
against the adoption of public health control measures
[20,51-54]. The above observations further suggest that
the role of market factors as risk commodity consumption
drivers is likely to be variable and context-dependent in
Asia and that TTCs may promote consumption most rap-
idly in markets with limited state competition.
The excessive consumption of alcohol is a significant
preventable risk factor for CVD, some cancers, cirrhosis
of the liver, road traffic injuries and some neuropsychi-
atric disorders [55]. Alcohol consumption is lowest in
the Islamic countries Indonesia and Malaysia where there
are high rates of abstention (Figure 2) [56]. Consumption
in other countries is relatively low in global comparison,
although the market data reported here likely underre-
ports actual volumes as it does not capture home or craft
production of traditional beverages common in many de-
veloping countries [55]. However in South Korea, China,
Thailand, Philippines, India, and Vietnam our data dem-
onstrates that alcohol consumption is increasing, primar-
ily through consumption of spirits and beer, as well as
Figure 1 Cigarette consumption (sticks per capita), 1998-2013 with projections to 2017, in selected Asian countries categorised by
income bracket.
Figure 2 Volume (litres per capita) of pure alcohol consumed by product category, 1998-2013 with projections to 2017, in selected
Asian countries categorised by income bracket.
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‘premium’ foreign brands. In China consumption of pure
alcohol per capita among people 15 years or older in-
creased 12-fold from 0.4 litres in 1952 to 4.9 litres in 2009
[57]. In the Philippines these figures were 0.7 and 4.6 litres
respectively [58]. Alcohol consumption and heavy episodic
drinking is higher amongst men than women in almost all
countries [56]. The alcohol industry of Asia appears to be
extensive. In the South-East Asia Region of the World
Health Organization alone it was estimated that more
than 600 factories and 1582 distributors were operating in
2003, employing more than 4 million people [59].
Countries are also at varying stages of ‘nutrition tran-
sition’, a dietary-shift from traditional diets rich in staple
foods and vegetables towards less healthy diets high in
ultra-processed foods such as biscuits, confectionary,
savoury snacks, processed meats and soft drinks [60-66].
As ultra-processed foods tend to be higher in sugar, salt,
saturated and trans-fats relative to unprocessed or minim-
ally processed foods, such dietary transitions are associ-
ated with rising rates of obesity and NCDs globally
[13,21,65,67-70]. Although Asian countries have relatively
low obesity prevalence rates, due to the high prevalence of
under-nutrition in early-life stages and differences in fat
patterning and cardio-metabolic effects at lower levels of
adiposity, some populations may be at greater risk of
diet-related NCDs in later life [65,71]. Asian popula-
tions are also more likely to develop diabetes at lower
levels of obesity, at younger ages, have more complica-
tions and die at younger ages [72,73]. Although con-
sumption of processed foods and soft drinks is highest
in the H-ICs, growth rates are mostly declining or stag-
nating in these countries (Figure 3). In contrast, it is
rapidly expanding in the U-MICs and L-MICs. In China
for example, processed food consumption increased 3.2-
fold from 19.6 kg per capita in 1999 to 63.4 kg in 2013.
In Vietnam, it increased 3.6-fold from 10.7 kg per capita
to 38.7 kg over the same period. Of concern, soft drink
consumption volumes are increasing in almost all coun-
tries. Thailand, Indonesia and the Philippines appear to
have volumes comparable to those of H-ICs [66].
Such trends indicate the burgeoning commercial suc-
cesses of alcohol, tobacco and food industries in the con-
text of rapidly-growing economies and rising household
incomes. When the social and economic externalities of
NCDs are accounted for they also constitute market
failures. Extensive macroeconomic losses can result from
increased health care expenditures, reductions in work-
force participation, productivity and consumer spending
[38,74–76]. Cumulative GDP losses related to NCDs be-
tween 2006-2015 were estimated at US$13.81 billion in
China, US$16.68 billion in India and US$4.18 billion in
Indonesia [38]. While the central and state governments
of India generated US$5.5 billion in excise taxes from al-
cohol in 2003-04, they spent an estimated US$6.2 billion
managing alcohol-related harms [77].
There are also significant microeconomic implications
for individuals and families living below or at the poverty-
line. The poor are more likely to die prematurely from
NCDs because of more limited access to treatments and
medicines but also because of ineffective or non-
existent NCD prevention policies [78,79]. Death or dis-
ability among men of working age can be devastating
for household welfare and the livelihoods of women
prematurely widowed [80]. High NCD-related medical
costs also have poverty implications. For example, the
risk of falling into poverty was estimated to increase by
40% among Indian households in which a household
member had an NCD [74].
Figure 3 Volume (kilograms/litres per capita) of processed foods and soft drink sales, 1998-2013 with projections to 2017, in selected
Asian countries categorised by income bracket.
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Trade and investment liberalization: creating favourable
conditions for TRCCs
In this next step we offer some explanations as to why
risk commodity consumption has increased and why it
might continue to increase across the region. From the
literature we identified three processes and five mecha-
nisms that link trade liberalization to NCDs through im-
pacts on risk commodity consumption and/or access to
medicines. The three processes of trade liberalization in-
clude: structural adjustment programmes and unilateral
liberalization, the multilateral system (i.e. General Agree-
ment on Tariffs and Trade/World Trade Organization),
and bilateral and regional preferential trade agreements
(PTAs). These processes can also be conceptualized as
successive layers of an evolving global trade, investment
and intellectual property regime that we will elaborate
on in the following sections. As it relates to risk commod-
ity consumption each of the three processes has been
more or less important at successive time points and our
analysis is therefore historical.
The five mechanisms that are evident in all three pro-
cesses of trade liberalization are as follows. First, trade
liberalization reduces tariff and non-tariff barriers to
trade and thereby facilitates imports and exports of risk
commodity products or the raw materials (e.g. tobacco
leaf or vegetable oil) used in their production. Second, it
can reduce barriers to trade in services (e.g. manufactur-
ing, distribution and advertising) and FDI thereby allow-
ing TRCCs to outsource their operations to domestic
corporations or to acquire them (and thus grow) through
mergers and acquisitions, as well as to expand their prod-
uct marketing and promotional activitiesa [13,14,81].
Third, trade agreements can, through strengthening in-
tellectual property rights, constrain access to medicines,
technologies and medical procedures used in NCD pre-
vention or treatment, or constrain the capacity of govern-
ments to develop legislation pertaining to risk commodity
advertising, labelling and composition [28,82]. Fourth,
through reducing tariff revenues and imposing significant
costs associated with compliance and negotiation, trade
agreements can indirectly impact health by reducing the
resources available to governments used to fund policy de-
velopment and implementation [83,84].
Five, through mandating processes managed by third
parties (e.g. the World Trade Organization) to oversee
implementation of trade agreements including dispute
settlement and enforcement mechanisms, the sovereignty
of nation states and their autonomy to make decisions re-
garding population health is diminished [85]. The above
and further sub-mechanismsb act to constrict domestic
‘policy space’, the freedom, scope and instruments available
to governments to develop policies and regulations that can
mitigate NCDs [14,86]. And because trade liberalization in-
creasingly allows transnational corporations to make global
investment decisions, it expands their capacity ‘to punish
and reward countries for their policy choices by relocating
investments and jobs’ [87,88 pg 13, 89]. The above mecha-
nisms therefore serve to expand the powers of TRCC’s rela-
tive to those of nation states.
Trade liberalization via structural adjustment
In the 1980s and 1990s trade liberalization accelerated
with the emergence of a global neoliberal development
agenda and the structural adjustment programmes (SAPs)
imposed on many countries by the International Monetary
Fund (IMF) and World Bank [90]. In return for much
needed finance, such SAPs required governments to pur-
sue reductions in their fiscal deficits (including cuts to
spending on health and other social services), to open
their economies to trade and FDI, to privatize state-owned
enterprises (SOEs), and to eliminate support for industries
serving domestic markets (import substitution) in favour
of export-orientated industries [90,91]. These policies also
created favourable conditions for the entry of TRCCs
seeking growth opportunities in emerging markets.
In India, for example, an early-1990s IMF bail-out
package required the Government to undertake exten-
sive economic liberalization that inadvertently resulted
in transformations in the domestic soft drink market
sector. Following the repeal of laws that prohibited the
repatriation of profits to foreign countries, PepsiCo en-
tered the Indian market in 1990 and engaged in heavy
competition with Parle, a domestic company and owner
of ‘Thums Up’, a cola brand with close to 85% of the
soft drinks market share [81]. After a prolonged absence
the Coca-Cola Company re-entered the market in 1993
through an acquisition of Parle, establishing the company
as market leader [92]. The resulting marketing and price
competition between these TRCCs was fierce with signifi-
cant impacts on consumption. According to Euromonitor
data, between 1998 and 2012 Indian soft drink sales qua-
drupled from 1.2 million to 4.4. million litres with a de-
cline in the retail selling price from US$0.6 to $0.4 per
litre (in fixed 2012 dollars, constant prices) [33].
Agricultural SAPs have also likely contributed directly
to a ‘nutrition transition’, in particular a regional shift
in vegetable oil consumption. These have pursued the
development of export-orientated cash-cropping. Be-
tween 1968 and 1993 the World Bank, for example,
loaned US$618 million for palm oil production projects
in Indonesia and US$383 million in Malaysia [93]. Food
and Agriculture Organization (FAO) data demonstrates
that Indonesian palm oil production alone increased
109-fold from 181,000 tonnes in 1968 to 19,760,000
tonnes in 2010. Indonesia’s top-two palm oil export
destinations were India and China, which in 2010, re-
ceived 5.3 million and 2.2 million tonnes respectively.
In the same countries edible oils have contributed more
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than any other food source to increased energy avail-
ability [13].
Trade liberalization via the multilateral system
The second process facilitating trade liberalization has
been the multilateral trade system. This accelerated in
1995 when the General Agreement on Tariffs and Trade
(GATT), the set of rules facilitating the reduction of bar-
riers to trade since 1947, was subsumed by the World
Trade Organization (WTO). The WTO serves today as
the central global trade negotiating platform, that unlike
the GATT system preceding it, includes a dispute settle-
ment system and legally-binding enforcement mechan-
ism [85]. A central tenet of WTO rules is the removal of
barriers to trade including tariff barriers (financial mea-
sures for restricting trade, such as import taxes) and
non-tariff barriers (other laws and regulations, such as
those designed to protect public health) [85]. The GATT
rules were also greatly expanded beyond trade in goods
to include ‘behind-the-border’ issues such as intellectual
property rights, trade in services, competition policy and
investment measures. We refer the reader to compre-
hensive reviews of the health implications of the various
WTO agreements [14,94-96].
Eightc of the sixty WTO agreements are highly signifi-
cant to risk commodities. The General Agreement on
Trade in Services (GATS) for instance opens countries to
trade and investment in services, although countries can
opt-in on a sector-by-sector basis. Services liberalization
can potentially enable TRCCs to contract out or acquire
key services at the global level, thereby integrating and
establishing control over global value chains (including re-
search & development➔ design➔ production➔ process-
ing ➔ manufacturing ➔ distribution ➔ marketing ➔
sales) [14,97]. Such value chains can be leveraged to
achieve economies of scale and drive down costs of pro-
duction by sourcing services from wherever they are least
expensive and regulation most favourable, processes that
can ultimately lead to the increased availability, afford-
ability and consumption of risk commodities [13]. Some
services can also directly contribute to expanding risk
commodity consumption. For example the ‘supermarke-
tization’ of Asia has been facilitated by the liberalization
of retail services and may contribute to the increased
availability of ultra-processed foods [98].
The Agreement on Trade-Related Aspects of Intellectual
Property Rights (TRIPS) expanded intellectual property
protections, requiring WTO members to allow patenting
of pharmaceutical products and processes (mandatory pat-
entability). Because the TRIPs agreement grants extensive
patent rights to transnational pharmaceutical firms it can
prevent the import or production of generic (i.e. non-
branded) drugs in developing countries, thereby potentially
increasing the costs or limiting the availability of essential
NCD medicines [28,99]. The TRIPS provisions also protect
other forms of intellectual property including trademarks,
brand names, product logos and trade secrets (information,
such as product content considered confidential to pro-
ducers). These provisions have direct implications for key
policy mechanisms targeting NCD risk commodities, in-
cluding advertising restrictions, product labelling and prod-
uct content disclosure [29].
Under the Agreement on Agriculture countries are ob-
ligated to reduce agricultural tariffs, domestic agricul-
tural supports and export subsidies [14]. This may not
only result in increased imports of low-cost food com-
modities but also render domestic agricultural producers
uncompetitive, resulting in reduced production of do-
mestic staples [100]. Domestic producers may be further
weakened when TRCCs import final products from or
source their supply inputs from the heavily subsidised
agricultural sectors of the US and EU [89].
The elimination of technical (non-tariff ) barriers to
trade was also broadened through the Agreement on
Technical Barriers to Trade. This ensures countries do
not adopt technical regulations (mandatory requirements
for product characteristics or production methods includ-
ing terminology, labelling and packaging requirements)
that create unnecessary barriers to trade. It recognizes the
use of technical regulation for the protection of ‘public
health or safety’ as a legitimate objective when it is consist-
ent with international technical standards. These can in-
clude, for example, standards pertaining to food, alcohol
and tobacco developed by relevant international organiza-
tions such as the WHO and Codex Alimentarius [101].
However, TRCCs have at times mobilized significant op-
position to the development of such standards, as demon-
strated during the development of the WHO’s Global
Strategy on Diet, Physical Activity and Health [102].
Under GATT articles XIV and XX the protection of
human health is recognized as an interpretive principle
allowing countries to adopt trade restrictive measures
when it is ‘necessary to protect human, animal or plant
life and health’ [14]. However, it must be demonstrated
that the action is both necessary to protect health but
also that no other less trade-restrictive measure is avail-
able. This provision has been interpreted very narrowly
in trade disputes and successful appeals on public health
grounds have been limited [14,97,100].
GATT-era liberalization: from bilateral sanctions to
multilateral enforcement
The first stage of multilateral liberalization with a bear-
ing on NCDs occurred under the pre-WTO GATT sys-
tem. While most countries included in this analysis were
signatory to the GATT prior to WTO establishment,
others, concerned with the protection of domestic indus-
tries from foreign competition, proceeded with a more
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cautious approach to determining the depth and timing of
trade liberalization [50,103]. On these grounds some did
not accede to the WTO until considerably later: China
in 2001, Cambodia in 2004, Vietnam in 2007 and Laos
in 2013.
In other countries, however, GATT-era trade disputes
were significant in the liberalization of tobacco trade.
Bilateral trade sanctions (non-GATT) were used as an
initial mechanism. For example the US Cigarette Export
Association, a tobacco industry lobby group, solicited
support from the US government to threaten trade sanc-
tions against South Korea, Japan, Taiwan and Thailand
unless they opened their domestic markets to US to-
bacco products [104]. In the latter three countries this
was successful, but to the significant detriment of public
health. Only one-year after the opening of the Japanese
market smoking prevalence doubled from 16% in 1986
to 32% in 1987, with most growth among adolescent
girls [105]. Similarly, in South Korea smoking prevalence
increased from 18.4% to 29.8% among adolescent males
and from 1.6% to 8.7% among adolescent females in a one
year period [104]. This is reflected in tobacco company
corporate documents demonstrating the deliberate and
strategic targeting of young women [106]. Thailand, how-
ever, maintained import restrictions arguing that US ciga-
rettes contained additives more harmful than those in
domestic cigarettes. Subsequently, in 1990, the US govern-
ment made a successful claim that these restrictions
violated GATT rules [107]. The GATT tribunal, however,
permitted Thailand to maintain existing tobacco control reg-
ulations including advertising restrictions, non-discriminatory
labelling, and ingredient disclosure laws [108]. As a result
Thailand has one of the most comprehensive tobacco con-
trol regimes globally and has maintained one of the lowest
smoking prevalence rates across the region [109]. None-
theless, this period constituted an important shift from bi-
lateral trade sanctions to multilateral enforcement for
opening markets to tobacco trade and consumption.
WTO accession: liberalization through conditionality of
membership
The second stage of multilateral liberalization has resulted
from accession to WTO membership. In order to join the
WTO a nation must declare all domestic policies that
have a bearing on the various WTO agreements and is
often required to modify such policies before membership
is granted. On these grounds the US challenged Vietnam’s
accession to the WTO claiming that its alcohol taxation
policies favoured domestic over foreign producers. China
and Taiwan also faced pressure during their WTO acces-
sion negotiations to privatize their state-owned tobacco
monopolies [110]. British American Tobacco (BAT) the
world’s most ‘transnationalized’ transnational tobacco
company (TTC) strategically lobbied EU, UK and US
government officials to achieve concessions from China
during its WTO accession negotiations. In 2004 the
Chinese Government implemented its commitments in-
cluding reduced tobacco import tariffs and eliminated
retail licensing (allowing retailers to sell foreign brands).
These changes were associated with increased tobacco
imports and reductions in foreign cigarettes prices [50],
although market penetration by TTCs remains low [43].
Some nations have made certain sectors and products
exempt from their WTO accession commitments. This
may have also influenced the scale of risk commodity
consumption. In India, for example, multi-brand retail
was excluded from its GATS commitments and has been
closed to foreign investment except through minority
joint ventures, resulting in very low levels of penetration
by transnational supermarket retailers [66,111]. Because
supermarkets can act as vectors for ultra-processed food
distribution [98], this may partly explain why India has
the lowest levels of consumption in the region (Figure 3).
Despite lengthy nationwide protests by farmers, retailers
and unions, however, a new law passed in September
2012 allowing up to 51% foreign ownership in the sector
will likely change the retail landscape significantly [112].
WTO Dispute Settlement System: liberalization through
trade disputes
The third stage of multilateral liberalization has been
through the WTO’s Dispute Settlement System. WTO
mediated trade disputes have opened multiple countries
to trade in risk commodities. Table 4 provides a simple
overview of trade dispute cases made under the GATT
rules pertaining to agriculture, alcohol, tobacco and
pharmaceuticals between 1996 and 2013. This demon-
strates that Thailand, Indonesia, Philippines and India
have used these rules to promote access for their domes-
tic producers to foreign and regional markets. For ex-
ample, in 2008, the Philippines claimed that Thailand’s
customs valuation procedures and comprehensive to-
bacco taxation scheme constituted unfair obstacles to to-
bacco importation [107].
What is also evident, however, is that Western nations
have even more frequently used WTO rules to promote
access to Asian markets for food and alcohol producers.
Tobacco appears to have been under-represented in
WTO trade disputes, most likely because of GATT-era
liberalization and bilateral sanctions we described earlier
had already resulted in market entry by TTCs. Of the 26
claims made against Asian nations, 21 were made by the
United States (US) and European Community (EC) alone
and of these 9 were against L-MICs and U-MICs. To the
contrary only 5 claims were made by L-MICs and U-MICs
against the US and EC. These differences likely reflect
asymmetries in markets sizes and therefore bargaining
power, but also the resources available to nations to make
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Table 4 Relevant trade dispute cases between 1995 and 2013 made under GATT rules
Country Signatory
to GATT
Accession
to WTO
Dispute claims made (as Complainant) Dispute claims against (as Respondent)
Agriculture Alcohol Tobacco Pharma. Agriculture Alcohol Tobacco Pharma.
Singapore 1973 1995 --- --- --- --- --- --- --- ---
Japan 1955 1995 --- --- --- --- US (2002); US (1997); EC (1997) US (1995)†; EC (1996)†;
Canada (1996)†
--- ---
Brunei Darussalam 1993 1995 --- --- --- --- --- --- --- ---
South Korea 1967 1995 --- --- --- --- US (1995); US (1995) US (1996; US
(1997); US (1999*; Australia 1999)*;
Canada (2009)*
EC (1997)†;
US (1997)†
--- ---
Malaysia 1957 1995 --- --- --- --- --- --- --- ---
China --- 2001 --- --- --- --- --- --- --- ---
Thailand 1982 1995 EC (1995); EC
(2003)‡; EC (2003);
Hungary (1996)
--- — --- Egypt (2000) --- Philippines
(2008)†
---
Indonesia 1950 1995 --- --- US (2010) --- US (2013) --- --- ---
Philippines 1979 1995 Australia (2002) --- Thailand
(2008)†
--- US (1997) EC (2009)†;
US (2010)†
India 1948 1995 --- --- --- Argentina (2001); EC;
Netherlands (2010)
US (2001); US, Australia, Canada,
NZL, Switzerland (1997)
EC (2008)† --- US (1997);
EC (1997)
Vietnam --- 2007 --- --- --- --- --- --- --- ---
Laos --- 2013 --- --- --- --- --- --- --- ---
Cambodia --- 2004 --- --- --- --- --- --- --- ---
Myanmar 1948 1995 --- --- --- --- --- --- --- ---
Totals 5 0 2 3 15 8 1 2
Years in brackets are when request was made for consultation; Pharma. = Pharmaceuticals; * = disputes pertaining to beef importation; † = disputes pertaining to taxation; ‡ = disputed agricultural subsidies made
under the Common Agricultural Policy of the EU; Data source: [118].
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or defend disputes which can involve often complex and
costly legal proceedings [90]. Developed countries not
only make more claims, they also win more [84]. One ana-
lysis demonstrated success rates of 74% and 50% for devel-
oped and developing countries respectively [113].
Most notably, the US, Canada and the EC have made
claims against Japan, South Korea, the Philippines and
India to reduce taxes on imported alcohol products. For
example, the national treatment rule was invoked to re-
move Japan’s high taxes on imported alcohol products.
This began with vodka as considered ‘like’ the traditional
spirit shochu but would subsequently include gin, rum,
whiskey, brandy and other spirits. Subsequently domes-
tic liquor prices dropped [110], although according to
our data consumption did not increase (Figure 2) and
we were unable to find further information to explain
this trend. The same rule was invoked by the EU in 1999
to eliminate South Korea’s preferential taxation scheme
determined as favourable to domestic alcohol producers
of the national spirit soju [114].
The threat of a WTO trade dispute can also result in
‘regulatory chill’, the non-adoption of domestic policies
arising not from a dispute, but from the threat of one. For
example, with the aim of reducing consumption of proc-
essed snack foods Thai civil society groups advocated for a
law requiring that products are labelled with a ‘Children
Should Take Less’ message as well as a traffic-light label-
ling system to indicate the sugar, fat, sodium and energy
content of products. Although considered by the Thai
Food and Drug Administration this was abandoned in
favour of an industry preferred Guideline Daily Amount
thumbnail labelling system when several WTO members
raised concerns about these policies during the Technical
Barriers to Trade committee deliberations [115].
Trade-Related Aspects of Intellectual Property Rights
agreement: implications for the region
The TRIPS agreement has a significant bearing on NCD
mitigation as it can determine the availability and afford-
ability of life-saving medicines. Under ‘TRIPS-flexibilities’
there are legal mechanisms, such as compulsory licensing,
available to governments to allow the production and im-
port of patented pharmaceuticals by domestic firms [28].
Under these rules, or in despite of them, Asian countries
have promoted access to medicines in two ways.
First has been through the interpretation and imple-
mentation of TRIPS-flexibilities, in particular by Thailand,
Malaysia and Indonesia. Moon and Szlezak have described
the actions taken by these governments in issuing com-
pulsory licenses for HIV/AIDS drugs since the 1990s.
Building off these developments Thailand more recently
extended TRIPS-flexibilities to NCD drugs. In 2007 it an-
nounced a compulsory license to a domestic firm to pro-
duce Clopidogrel, a blood-thinning drug for hypertension
patented by French firm Sanofi (under the brand name
Plavix). In 2008, compulsory licenses were also announced
for four cancer drugs: Erlotinbi, Docetaxel, Letrozole and
Imatinib (the latter was not implemented due to interven-
tion by Novartis) [116].
The second is exemplified by India through its adop-
tion of stand-alone national patent licensing legislation
that gives significant weighting to public health protection.
Most developing countries usually have small or non-
existent pharmaceutical industries and must therefore im-
port patented medicines from developed countries. This
often contributes to large health-cost and balance of pay-
ments deficits [28]. India is an exception. Known as the
‘pharmacy of the developing world’ it has a highly com-
petitive domestic pharmaceutical industry that not only
produces large quantities of generic medicines at very
low-cost, but also exports two-thirds of production to
LMICs [99]. The legality of India’s pharmaceutical sector
is, for these reasons, of particular relevance to NCD miti-
gation across Asia.
In 1997 the US and EU bought complaints against India
alleging that the absence of a patent protection system vi-
olated the TRIPS mandatory patentability rule. India used
TRIPS-flexibilities and made full use of the transition
period allowed for developing countries under WTO ac-
cession rules to develop its national patenting legislation.
This scheme became fully operational in 2005 [117]. Un-
like the Thailand and Indonesian schemes that invoke
TRIPS-flexibilities in order to issue compulsory licenses
on patents already recognised by their national laws, the
Indian scheme can invoke TRIPS-flexibilities but also pre-
clude the granting of patents in the first place [116].
As a result India has been the centre of a legal battle-
ground that has broad repercussions for access to NCD
medicines. Two cases pertain to cancer medication. In a
first case the company Novartis was refused a patent for
the leukaemia drug Imatinib, allowing Indian generic
companies to supply the drug at almost one twentieth of
the price (US$124-174 versus $2478 per month). In a
second, although the company Bayer was granted a patent
for its renal cancer drug Sorafenib (marketed as Nexavar),
the Indian Government issued a compulsory license to an
Indian company that allowed supply at more than one for-
tieth of the branded price (US$125 versus $5500 per
month) [99,117].
The future of TRIPS and tobacco labelling policy in
Asia appears to be untested in this space (although as
described earlier, Thailand was able to maintain tobacco
control measures under earlier GATT rules). However
Asian nations such as Malaysia and Thailand continue
as ‘observers’ of the recent WTO challenge to Australia’s
plain packaging regulation bought by a number of tobacco
producing countries that could set an important prece-
dent for tobacco control in the region [118].
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Liberalization via bilateral and regional preferential trade
agreements
The third process is the more recent proliferation of bilat-
eral and regional preferential trade agreements (PTAs).
While PTAs are often referred to as free trade agreements
they are best described as ‘preferential’ trade agreements
because they are never truly ‘free’, but rather provide
signatories with more favourable (and thus preferential)
terms of trade than non-signatories. While bilateral invest-
ment treaties (BITS) have been numerically more com-
mon, particularly so during the 1990s, today regional
PTAs with investment provisions are more economically
significant. Thus the most significant contemporary trend
in the global trade regime is best described as multilateral-
ism with ‘regionalism on the rise’ [26].
Regional and extra-regional economic integration in
Asia greatly accelerated following the 1998 Asian Finan-
cial Crisis [4]. PTAs involving at least one Asian country
increased from 46 in 1998 to 257 in 2013. Of these 50
were in the proposed stage, 75 were under negotiation
and 132 had been signed. One possible reason for this
growth in PTAs is that they provide a mechanism for
accelerated trade liberalization as an alternative to the
slow-pace of multilateral (i.e. WTO) negotiations [119].
This may also constitute a commercial strategy, known as
‘forum-shifting’, that offers TRCCs and their representa-
tive governments an alternative mechanism for opening
markets to trade and investment [5]. Initial agreements
may also trigger a domino-effect as other countries initiate
further PTAs to retain trade competitiveness [119].
The second important trend is that PTAs are becom-
ing increasingly ‘deep’ with commitments and conces-
sions that go beyond those required by the WTO system
[120]. First they include provisions consistent with the
existing WTO agreements but also commitments that
go beyond them, thus referred to as ‘WTO-plus’ (agree-
ments also take this nomenclature e.g. ‘TRIPS-plus’). They
also include commitments outside of the current WTO
framework, referred to as ‘WTO-X’ including those on
intellectual property rights, investment and competition
[120]. These are not so much concerned with facilitating
‘cross-border’ trade but with integrating ‘behind-the-
border’ domestic policies that represent threats to glo-
bal intra and inter-firm supply chains [121].
The implications for public health have generated sig-
nificant concern for a number of reasons. First, while
the multilateral system provides flexibilities on public
health and safety grounds these can be excluded from or
highly restricted within PTAs [14,28]. Second, while under
the multilateral system trade disputes are made by one
government against another, investor-state dispute settle-
ment (ISDS) mechanisms in many PTAs allow corporate
investors to file legal proceedings directly against govern-
ments to recuperate losses resulting from the adoption of
domestic regulations (including health regulations) [29].
Third, with significant asymmetries in economic and
therefore bargaining power, developing countries are more
likely to make deep concessions in PTA negotiations; to
date this has been most evident within investment and in-
tellectual property provisions of such agreements. Finally,
PTA negotiations are usually ‘closed door’, therefore lacking
the greater transparency of multilateral negotiations [122].
The net effect is to not only further constrain the
domestic public health policy mechanisms available to
signatory governments (i.e. reduce their ‘policy space’),
but to also greatly expand the power of TRCCs and rep-
resentative governments to dispute policies enacted by
governments to prevent or control NCDs. Restrictions
on risk commodity advertising could, for example, be rep-
resented as barriers to cross-border trade in advertising
services. Compliance costs and evidence requirements
imposed on countries aiming to regulate advertising
could also act as a deterrent. The South Korea-US PTA
(KORUS), for example, contains stringent criteria on
countries wishing to regulate the supply of services.
This concern has been flagged as a potential threat to
legislation targeting the marketing of foods and bever-
ages to children [82,115].
The impacts of PTAs on NCD risk factor consumption
can be significant. A recent analysis demonstrated that a
PTA with the US was associated with a 63.4% higher soft
drink consumption per capita compared to countries with
no US PTA [21]. This is of concern given an association
between soft drink consumption, obesity and type-2 dia-
betes [123]. The North American Free Trade Agreement
(NAFTA) has been particularly significant in the case of
Mexico. A combination of subsidised agricultural produc-
tion in the US (propagated by the US Farm Bill), and in-
creased processed food exports and FDI by US firms into
Mexico have had deleterious impacts on public health nu-
trition [124,125]. Mexicans now consume more than 300
litres of soft drinks per capita per year, the highest con-
sumption globally. In 2011, 32.4% of Mexican adults were
reported as obese, the second highest rate among OECD
countries [21].
Several PTAs are or will be notably significant to NCDs
in Asia. The 2003 US-Singapore agreement eliminated to-
bacco tariffs and included an ISDS allowing investors to
directly challenge government regulations [110]. KORUS
is another. It opened South Korea to US agricultural im-
ports, most significantly for beef, previously limited on
public safety grounds following fears over bovine spongi-
form encephalopathy (mad-cow disease). The US trade
negotiator was also pressured by a diversity of business
groups, including alcohol and tobacco companies, to not
exclude any service, sector or product from the agreement
[29]. KORUS was an important agreement, not only be-
cause South Korea made ground-breaking concessions
Baker et al. Globalization and Health 2014, 10:66 Page 13 of 20
http://www.globalizationandhealth.com/content/10/1/66
but also because it now serves as a template for future
US-led trade negotiations including the Trans-Pacific
Partnership Agreement (TPP) currently under negoti-
ation [126].
The Trans-Pacific Partnership Agreement
In economic terms the TPP has the potential to be the
most significant trade policy of the 21st Century. The
twelve negotiating countries include Australia, Brunei,
Canada, Chile, Japan, Malaysia, Mexico, New Zealand,
Peru, Singapore, the US and Vietnam. South Korea may
later join the negotiations. Together these counties have
an aggregate GDP of US$28 trillion (40% of the world
total), and were attributed to 27% of world exports worth
US$6 trillion in 2011. The TPP is also significant because
it serves as an interim arrangement prior to a more com-
prehensive Free Trade Area of the Asia Pacific (FTAAP)
that may incorporate a greater number of countries [127].
The TPP constitutes a significant threat to public
health policies targeting risk commodities in the partici-
pating countries of Asia [115,121,126]. Although some
countries have proposed that the agreement should ‘sup-
port each Party’s right to protect public health, including
by facilitating timely access to affordable medicines’ and
that countries can ‘adopt measures necessary to protect
public health and nutrition’ the US and Japan have op-
posed adoption of these provisions [As quoted in 131].
A leaked draft text demonstrates that investment provi-
sions of the TPP do not allow any general exceptions on
health and consumer protection grounds [115,129].
Other key provisions of concern include those on regu-
latory coherence and transparency that require govern-
ments to consult industry and disclose information during
domestic policy-making processes [115]. Unlike the WTO
system where arbitration is between nation-states, the
TPP draft text includes an ISDS mechanism that investors
(corporations) can utilize to pursue compensation from
governments for losses resulting from the adoption of
health regulations [121]. Although these have been incor-
porated into PTAs for some time, Philip Morris Asia has
recently pursued compensation from the Australian Gov-
ernment for its plain packaging tobacco legislation using
an ISDS provision within Australia’s Bilateral Investment
Treaty with Hong Kong [130]. The threat of similar future
arbitration from TRCCs may promote regulatory chill
among domestic policy-makers (i.e. reluctance to adopt a
given policy mechanisms through fear of an investor
dispute) and thereby constrain future innovation in public
health policy targeting risk commodities [121,127]. The
example also indicates that TRCCs can leverage PTAs
from whichever country they have a subsidiary and from
wherever their legal standing most favourable.
Intellectual property rights (IPR) provisions of the TPP
are also highly contentious. The US has pushed for a
broad approach to IPR akin to the KORUS agreement
on patents, copyrights, trademarks and trade secrets.
This includes demands that animals, plants and medical
procedures are subject to patent protection [128]. US
negotiators have also tabled a TRIPs-plus ‘access to med-
icines’ provision, which includes patent term extensions,
data exclusivity and patent linkages. This offers compan-
ies an ‘access window’ effectively extending the length of
patent monopolies while companies seek marketing ap-
proval for their drugs in TPP member country markets.
The intention of patent linkage is to connect drug regu-
latory agencies and to require a mandatory check that
the marketing of new (e.g. generic) drugs do not infringe
on existing patents. Data exclusivity is a period when a
patent holder may withhold test data from generic man-
ufacturers thereby constraining the ability to manufac-
ture it (although this may be voluntary for developing
countries) [127,128]. Together, these provisions have the
potential to restrain access to and increase prices of
NCD medicines and technologies in the region.
Discussion: a research agenda for diagnosing and
strengthening regulatory capacity
There are several limitations of this analysis. It reviews
the evidence as it applies to a selection of Asian countries,
excluding many where risk commodity consumption is
also exerting a significant health and economic toll. None-
theless, we capture countries with the largest population
sizes. The market data we have used to describe changes
in risk commodity consumption are imperfect measures
because these do not capture those commodities manufac-
tured in the home or sold through informal (non-market)
productions systems, nor for wastage. However unlike sur-
vey data these data are not subject to recall bias, and their
abundance allowed for comparisons between countries
over time [21]. Most importantly, the paper focuses on
risk commodity consumption and does not highlight the
ways in which trade liberalization can improve health dir-
ectly through for example promoting access to fruits and
vegetables, or indirectly through contributing to broader
economic development. Nor does it elaborate on the in-
direct effects of trade liberalization on NCDs through, for
example, changes in access to health care services or
heightened employment insecurity resulting from chan-
ging labour market structures [14].
Despite these limitations this article has provided a
synthesis of the literature and presented data on the
considerable health and economic externalities resulting
from risk commodity consumption in the region. It has
demonstrated how successive layers of the global trade
regime have contributed to the proliferation of the to-
bacco, alcohol and ultra-processed food industries, and
how they might constrain access to NCD medicines across
Asia. The findings bring into play pressing questions for
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future research. How in the context of increasing trade
liberalization can public health responses to risk commod-
ity consumption in Asia be strengthened at the global, re-
gional and national levels? We offer some directions for
future work on strengthening NCD governance capacity
in Asia.
In 2011 the United Nations General Assembly adopted
the Political Declaration on the Prevention and Control
of Non-communicable Diseases (UNPDNCD), the high-
est multilateral mechanism addressing NCDs [131].
Although trade was referred to as an important sector
for intervention in the regional consultations leading up
to the UNHLM its inclusion within the Political Declar-
ation was opposed by the US and EU [132]. Inter-
national standards developed by WHO will, however, be
important to protecting domestic policy space to address
risk commodities [28,133]. The 2003 Framework Conven-
tion on Tobacco Control (FCTC) (adopted under Article
19 of the WHO constitution) is a legally binding treaty
that may be used to uphold domestic tobacco legislation
in trade dispute arbitration, as exemplified recently in ar-
guments by Australia to defend its plain packaging legisla-
tion in response to WTO dispute arbitration, although a
ruling has yet to be made [134].
For ultra-processed foods and alcohol, however, inter-
national agreements are non-binding recommendations
(adopted under Article 23), the 2004 Global Strategy on
Diet, Physical Activity and Health, and 2010 Global Strat-
egy to Reduce the Harmful Use of Alcohol respectively.
The former states that no provisions in the recommenda-
tions should be construed as justification for trade restrict-
ive measures while the latter recognizes the important
role of trade as a determinant of alcohol consumption
[135,136]. The feasibility and approaches for strengthen-
ing international standards to address ultra-processed
foods and alcohol have been explored elsewhere, and may
include the development of more selective mechanisms
targeting particular products (e.g. soft drinks) or services
(e.g. advertising) as well as standards set by other inter-
national organizations including Codex Alimentarius
[137–139]. We need to understand much better the role
of Asian nations in developing the above and other rele-
vant international standards, particularly explaining any
change as their increasing economic and political power
leads to greater influence in global health governance
more generally [140,141].
Countries may adopt provisions in the aforementioned
international agreements as domestic policies so long as
they are consistent with international trade obligations –
that is they do not arbitrarily or unjustifiably discriminate
or act as disguised barriers to trade. Increasing participa-
tion in trade negotiations, however, requires countries to
strengthen regulatory capacity in terms of monitoring trade
agreements and ensuring compliance with international
obligations, but also in terms of managing associated
risks and ensuring adequate protections for public
health [84,142]. Achieving these objectives can be a sig-
nificant challenge for poorer countries, especially when
the negotiating delegations of rich countries are likely to
be backed by deep-pocketed TRCC lobbyists and exten-
sive legal teams [143]. They may also struggle to develop
the scientific and legal expertise required to evaluate the
costs and benefits of entering into trade agreements
[144]. This suggests that without the development of such
capacities trade agreements have the potential to be an
important driver of health inequities between countries in
the region [126].
The WHO Global Action Plan for the Prevention
and Control of Noncommunicable Diseases 2013–2020
(GAPNCD) recognizes the role of WHO in offering
technical assistance to developing country governments
to mitigate the impact of trade agreements on health.
Such assistance may be critical to addressing the prolif-
eration of risk commodity industries in Asia, especially
in developing countries with limited regulatory capacity.
The GAPNCD also calls on the FAO to ‘Support minis-
tries of agriculture in aligning agricultural, trade and
health policies’ and on the WTO to ‘…support minis-
tries of trade in coordination with other competent gov-
ernment departments (especially those concerned with
public health), to address the interface between trade
policies and…noncommunicable diseases’ [145], p74. Al-
though the use of health impacts assessments (HIAs) have
been proposed, we do not yet fully understand the efficacy
of using HIAs to make trade work for rather than against
health in practice [146]. Research is required on the effects
of frameworks designed specifically to monitor the im-
pacts of trade agreements on risk commodity consump-
tion, as developed recently in the nutrition space [95].
This also raises research questions around capacity-
building for global health diplomacy and the effects of
providing developing country officials with the requisite
training and skills to participate effectively in trade and
health negotiations [147].
The potential opportunities at the regional level are
under researched in the current literature. Despite the
primacy they give to trade liberalization, ASEAN and
the Asia Pacific Economic Cooperation forum have re-
cently demonstrated increased commitment to address-
ing regional health issues, in particular infectious disease
threats [148,149]. As others have noted, however, ASEAN
member states have been resistant to attempts to develop
regional policy mechanisms that impinge on their national
sovereignty. Decision-making processes have been slow
due to a ‘rule-by-consensus’ culture and their highly politi-
cized nature (the ‘ASEAN’ way) [149]. The ASEAN Health
Ministers Meeting is held every two years yet it has con-
fined its work largely to infectious disease control and
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disaster preparedness, with agreements to date focused
largely on sanitary and phyto-sanitary measures [150].
However, in a joint statement in 2012, ASEAN Plus Three
Health Ministers recognized the significant NCD burden
in the region and affirmed their commitment to imple-
menting the UNPDNCD [151]. Actions to address NCDs
have fallen under the ASEAN Strategic Framework on
Health Development (2010-2015) with working groups
established to address regional tobacco control and
NCDs, but not ultra-processed foods or alcohol [152].
As scholars, we need to understand the extent to which
ASEAN and other regional bodies constitute an effect-
ive platform for generating regional positions or mecha-
nisms to address trade and risk commodities, especially
when one of its key constituent members, Indonesia, is
yet to ratify the FCTC.
Asia is also home to ‘light-house’ countries taking uni-
lateral action to address risk commodity consumption.
Thailand, for example, has one of the most comprehen-
sive tobacco control regimes globally (although as shown
in Figure 1 consumption levels remain relatively high)
[108]. It has implemented a hypothecated 2% levy on al-
cohol and tobacco sales to fund its Thai Health Promo-
tion Foundation [153]. It is also a world leader in
addressing health and trade issues. Its National Com-
mittee on International Trade and Health, established
by the National Health Assembly, brings together offi-
cials from ministries of industry, public health, food and
agriculture, as well as various professional groups to in-
vestigate how trade agreements affect health, to advo-
cate for the inclusion of health in trade negotiations and
to coordinate action between concerned agencies [42].
Other governments in the region may consider the es-
tablishment of their own ministerial level and intergov-
ernmental bodies with a mandate to address trade and
health related issues. As mentioned earlier the WHO
and other international organizations have key roles to
play in building capacity here. Development assistance
for health programmes may also focus work in this area.
However, caution is warranted; although the EU has
done this recently with assistance for developing South-
East Asia nations to establish patent offices, this also
strengthens patent compliance in the region and may
therefore favour the interests of European pharmaceut-
ical companies (4). Earlier we described how India has
adopted a novel domestic patent regulatory regime that
offers strong public health protections to improve ac-
cess to essential NCD medicines. This prompts the need
for a seam of research into whether cooperation be-
tween countries in order to share such regulatory les-
sons is or could be important to strengthening policy
responses to NCDs across the region [84].
This article has not explicitly demonstrated the mech-
anisms by which the expanding growth and power of
TRCCs facilitate increased risk commodity consump-
tion. The understandings of such mechanisms appears
to be theoretically and empirically underdeveloped in
the public health literature. The distinct characteristics
of corporate activity within the risk commodity indus-
tries of Asia also remain opaque. Fundamentally, how-
ever, strengthening policy and governance responses to
address NCDs will require directly challenging the
power of these commercial actors. Globalization en-
hances the power of TRCCs to influence international
and national policy agendas because nation states must
increasingly compete with one another to attract and re-
tain the investments and jobs they provide [79,87-89],
especially when such companies are among the largest
operating in LMICs [20]. This creates a difficult paradox
for government regulators who must balance the oppor-
tunities for economic development these companies
provide and the public health and welfare implications
of those investments [20]. Governments of the US, EU
and Japan have implemented comprehensive policies
and programmes to address risk commodity consump-
tion at home, but TRCCs located in their countries are
now driving an NCD pandemic abroad. Trade and in-
vestment liberalization may, therefore, act as a mechan-
ism whereby these countries externalize the social and
economic costs arising from their risk commodity in-
dustries while benefiting from the expatriated profits of
the same industries [89].
Conclusions
In a world characterised by increasing economic globali-
zation it is important to understand how markets and
commercial actors operate in ways that are detrimental or
beneficial to health [154]. This article has demonstrated
how the evolving layers of the international and regional
trade regimes have facilitated increased market penetra-
tion by transnational tobacco, alcohol and ultra-processed
food corporations and thereby driven consumption of
these risk commodities in Asia. It has also elaborated on
the implications for access to NCD medicines. Increased
participation in trade agreements requires governments
and public health actors to strengthen regulatory capacity
to ensure adequate protections for public health. This art-
icle provides a justification for developing such capacity
in order to defend public interests against the coordi-
nated and extensive litigation strategies of TRCCs and
their representative governments in trade negotiations
and disputes [143]. Further research is warranted to
understand how this can be achieved at the multilateral,
regional and national levels. Without such capacity,
trade agreements may become an increasingly import-
ant driver of risk commodity consumption, NCDs and
health inequities between countries in the Asia region.
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Endnotes
aA comprehensive description of the respective risk
commodity industries of Asia and the mechanisms by
which transnational risk commodity corporations facilitate
increased consumption is the subject of a forthcoming art-
icle by the same authors. These mechanisms include for
example increased market concentration, more intensive
competition, more intensive advertising, initial reductions
in product pricing and in some cases aggressive lobbying
against the adoption of public health control measures.
bThe constriction of domestic policy space is further
facilitated in three ways. First, through the layering of
globalized and more difficult processes of making health
policy onto existing domestic policy-making processes
(procedural constriction). This can result in ‘regulatory
chill’ whereby the potential threat of trade sanctions or
costly litigation can deter government institutions from
initiating policy processes. Second, through limiting the
availability of policy instruments available to governments
(substantive constriction) including those pertaining to
advertising restrictions, mandatory product labelling and
product content disclosures. Third, by expediting a shift
from public to private provision of goods and services
that expands the economic and regulatory power of
private relative to public sector actors (structural con-
striction) [97].
cWTO trade agreements most relevant to risk commod-
ities include: (i) General Agreement on Trade in Services
(GATS); (ii) Agreement on Agriculture (AoA); (iii) Agree-
ment on the Application of Sanitary and Phytosanitary
(SPS) measures; (iv) Agreement on Trade-Related Aspects
of Intellectual Property Rights (TRIPS); (v) Technical
Barriers to Trade (TBT) Agreement; (vi) Dispute Settle-
ment Understanding; (vii) Agreement on Trade-Related
Investment Measures (TRIMS); and, (viii) Agreement
on Government Procurement (AGP) [95].
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